Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cgh.2019.04.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tumor-infiltrating lymphocytes: A new hope.
Cancer Cell
August 2024
Immunology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; Center for Immunization and Infection Research in Cancer, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Tumor-infiltrating lymphocytes (TILs) can be massively expanded from resected tumors and used as a cellular treatment for advanced malignancies. TILs require a preparative non-myeloablative chemotherapy followed by an abbreviated course of interleukin-2. Here, we review the historical development of TIL therapy and discuss potential solutions to ongoing roadblocks that may result in broader and improved efficacy for patients afflicted with treatment-refractory, advanced cancer.
View Article and Find Full Text PDFThe lingering challenge: addressing vaccine hesitancy in a post-pandemic world.
Cent Eur J Public Health
December 2023
Centennial High School, Corona, California, United States.
Last time the world faced a deadly pandemic was the H1N1 Spanish flu in 1918, which affected almost one-third of the world's population (500 million people). Since then, almost 100 years later, we are now facing another pandemic of the SARS-CoV2 virus (COVID-19), which is still endemic to this day. As the technology evolved during those 100 years, an effective vaccine for COVID-19 was produced within only a year, a huge feat.
View Article and Find Full Text PDFEnzyme-controlled, nutritive hydrogel for mesenchymal stromal cell survival and paracrine functions.
Commun Biol
December 2023
University Paris Cité, CNRS, INSERM, ENVA, B3OA, Paris, France.
Culture-adapted human mesenchymal stromal cells (hMSCs) are appealing candidates for regenerative medicine applications. However, these cells implanted in lesions as single cells or tissue constructs encounter an ischemic microenvironment responsible for their massive death post-transplantation, a major roadblock to successful clinical therapies. We hereby propose a paradigm shift for enhancing hMSC survival by designing, developing, and testing an enzyme-controlled, nutritive hydrogel with an inbuilt glucose delivery system for the first time.
View Article and Find Full Text PDFConformation-selective rather than avidity-based binding to tumor associated antigen derived peptide-MHC enables targeting of WT1-pMHC low expressing cancer cells by anti-WT1-pMHC/CD3 T cell engagers.
Front Immunol
December 2023
Biologics Engineering, Biopharmaceutical R&D, AstraZeneca, Gaithersburg, MD, United States.
T cell engagers, a category of T cell-retargeting immunotherapy, are rapidly transforming clinical cancer care. However, the lack of tumor-specific targets poses a significant roadblock for broad adaptation of this therapeutic modality in many indications, often resulting in systemic on-target off-tumor toxicity. Though various tumor-derived intracellular mutations provide a massive pool of potential tumor-specific antigens, targeting them is extremely challenging, partly due to the low copy number of tumor associated antigen (TAA)-derived pMHC on tumor cell surface.
View Article and Find Full Text PDFBenefits and concerns of seeking and experiencing lucid dreams: benefits are tied to successful induction and dream control.
Sleep Adv
September 2022
Department of Psychology, Northwestern University, Evanston, IL, USA.
Therapies focused on lucid dreaming could be useful for treating various sleep disorders and other conditions. Still, one major roadblock is the paucity of systematic information on the consequences of attempting these sorts of dreams. The current study sought to quantify positive and negative aspects of seeking lucid dreams, describe their phenomenology in detail, and identify features associated with positive or negative experiences.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!